DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Can M&M maintain its growth momentum with new product launches ?
9/05/2025
Promoter ownership in India's top 500 companies hits record low of 49.5%
9/05/2025
Will the escalating India-Pakistan conflict continue to rattle stock market ?
9/05/2025
RBI eases FPI rules on corporate bonds to boost foreign inflows
8/05/2025
Putin says had 'productive' talks with 'dear friend' Xi
8/05/2025
Big explosion reported in Lahore ; flight suspension at Karachi, Lahore, Sialkot airports
8/05/2025
